Burning Rock Biotech (NASDAQ:BNR) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• Weiss Ratings has reissued a "sell (D-)" rating for Burning Rock Biotech (NASDAQ:BNR), indicating continued negative sentiment towards the stock.
• Burning Rock Biotech shares recently traded at $8.90, down 1.2%, with a market cap of $95.76 million and a negative P/E ratio of -4.68.
• In the latest quarter, Burning Rock Biotech reported a negative EPS of ($0.15) and a revenue of $20.74 million, with a negative return on equity of 23.61%.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Burning Rock Biotech Trading Down 1.2%

Shares of Burning Rock Biotech stock traded down $0.11 on Wednesday, reaching $8.90. The stock had a trading volume of 7,303 shares, compared to its average volume of 30,490. The business's 50 day moving average is $8.27 and its two-hundred day moving average is $5.24. The company has a market cap of $95.76 million, a P/E ratio of -4.68 and a beta of 0.98. Burning Rock Biotech has a 1 year low of $2.18 and a 1 year high of $11.12.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last posted its earnings results on Monday, September 8th. The company reported ($0.15) earnings per share (EPS) for the quarter. Burning Rock Biotech had a negative return on equity of 23.61% and a negative net margin of 26.04%.The firm had revenue of $20.74 million during the quarter.

Hedge Funds Weigh In On Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. Citadel Advisors LLC purchased a new stake in shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 12,267 shares of the company's stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.12% of Burning Rock Biotech as of its most recent SEC filing. 30.03% of the stock is owned by institutional investors.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.